Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jun:57:86-94.
doi: 10.1016/j.breast.2021.03.002. Epub 2021 Mar 23.

Clinical outcomes of platinum-based chemotherapy in patients with advanced breast cancer: An 11-year single institutional experience

Maria Alice Franzoi  1 , Rita Saúde-Conde  2 , Sofia Cristóvão Ferreira  2 , Daniel Eiger  3 , Ahmad Awada  4 , Evandro de Azambuja  5
Affiliations

Clinical outcomes of platinum-based chemotherapy in patients with advanced breast cancer: An 11-year single institutional experience

Maria Alice Franzoi et al. Breast. 2021 Jun.

Abstract

Background/methods: Although the prognosis of metastatic breast cancer (BC) has improved, some patients still develop high burden metastases or visceral crisis (VC) and polychemotherapy is commonly used in these cases. Data reporting the real effectiveness of this strategy are scanty. Therefore, the outcomes of patients with metastatic BC treated with platinum-based chemotherapy (P-ChT) at the Jules Bordet Institute during the period of January 2008 and December 2018 were retrospectively reviewed. The presence of VC was defined according to ABC 4 criteria.

Results: 441 patients were identified: visceral metastases were observed in 430 (97.5%) while 261 (59.2%) presented VC. As for metastatic BC subtype, 255 (57.8%) had ER-positive/HER2-negative, 41 (9.3%) ER-positive/HER2-positive, 34 (7.7%) ER-negative/HER2-positive and 111 (25.1%) triple-negative BC. Median number of prior treatment lines was 3.8 (0-12). Median OS with P-ChT in the entire cohort was 6.13 months. Patients with VC had lower OS than patients without VC (8.6 vs 3.7 months; p < 0.001). On multivariate analysis, the variables correlated with worse OS were hyperbilirubinemia (HR 1.90; 95% CI 1.34-2.75), ECOG ≥2 (HR 1.77; 95% CI 1.13-2.78) and ECOG ≥3 (HR 2.52; 95% CI 1.48-4.28), and >3 previous treatment lines (HR 2.27; 95% CI 1.53-3.21). Of the 261 patients with VC, 106 (40.5%) presented a resolution of the VC which correlated with better OS (9.3 vs 2.0 months, HR 0.27; 95% CI 0.21-0.36).

Conclusion: Patients who overcome VC benefit from P-ChT with OS similar to patients without VC. In this analysis, hyperbilirubinemia, poor ECOG and >3 previous treatment lines were significant prognostic factors in the overall study population.

Keywords: Metastatic breast cancer; Platinum-based chemotherapy; Visceral crisis.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest MAF: none. RSC, SF: Travel grant from Pfizer for the ESMO conference 2019. DE: Funding for his fellowship (2018–2019: Novartis. Speaker fee: Janssen. AA: Advisory role, speaker fees and research funding for his institute from: Roche, Lilly, Amgen, EISAI, BMS, Pfizer, Novartis, MSD, Genomic Health, Ipsen, AstraZeneca, Bayer, Leo Pharma. EA: honoraria and advisory board: Roche/GNE, Novartis, Seattle Genetics and Zodiacs; travel grants: Roche/GNE, GSK/Novartis; co-principal investigator of the LORELEI trial (NCT02273973). Research grant for his institute: Roche/GNE, Astra-Zeneca, Novartis, and Servier.

Figures

Fig. 1
Fig. 1
Flow chart of study population and patient selection.
Fig. 2
Fig. 2
Median overall survival with platinum-based polychemotherapy in the whole cohort.
Fig. 3
Fig. 3
Median overall survival with platinum-based polychemotherapy patients with and without visceral crisis.
Fig. 4
Fig. 4
Kaplan Meier curves according to visceral crises resolved, not resolved and without visceral crisis.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Waks A.G., Winer E.P. Breast cancer treatment: a review. J Am Med Assoc. 2019;321:288–300. - PubMed
    1. Harbeck N., Penault-Llorca F., Cortes J. Breast cancer. Nat Rev Dis Primers. 2019;5(1–31) - PubMed
    1. Prat A., Perou C.M. Deconstructing the molecular portraits of breast cancer. Mol Oncol. 2011;5(5–23) - PMC - PubMed
    1. Sørlie T., Perou C.M., Tibshirani R. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci Unit States Am. 2001;98:10869–10874. - PMC - PubMed
    1. Perou C.M., Sørlie T., Eisen M.B. Molecular portraits of human breast tumours. Nature. 2000;406:747–752. - PubMed